Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-22
2008-04-22
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07361669
ABSTRACT:
This invention provides compounds that are inhibitors of the TGF-β signaling pathway. The compounds are represented by formula I:where A′ is N or CH; Ring B is preferably an triazolyl, imidazolyl, or thiazolyl ring; —X-D- is a linker group; and G is an optionally substituted aryl or heteroaryl ring. The compounds are useful for treating cardiovascular disease.
REFERENCES:
patent: 0372445 (1994-03-01), None
patent: WO 91/18885 (1991-12-01), None
patent: WO 00/61576 (2000-10-01), None
patent: WO 01/37835 (2001-05-01), None
patent: WO 02/14311 (2002-02-01), None
Czarnocka-Janowicz, A. et al., “Synthesis and pharmacological activity of 5-substituted-s-triazole-3-thiols,”Pharmazie, Veb Verlag Volk Und Gesundheit, vol. 46, No. 2 (1991), pp. 109-112.
Mehrotra Mukund
Pandey Anjali
Scarborough Robert M.
Henley III Raymond J.
Millennium Pharmaceuticals Inc.
LandOfFree
Compositions and method for inhibiting TGF-β does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and method for inhibiting TGF-β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and method for inhibiting TGF-β will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2790239